Some research that discussed the relationship between RANKL’s inhibitor OPG and NAFLD have provided clinical hints for the possible role of RANKL in NAFLD [41,42,43]. Here, TNFRSF11B is linked to metabolic dysfunction-associated steatotic liver disease.